fda compounding semaglutide crackdown 2025 news FDA Intensifies Crackdown on GLP-1 Compounding

FDA proposes a new GLP-1 compounding crackdown

25.45

★★★★☆4.8 (126)

The Food and Drug Administration's crackdown on cheaper, independently produced versions of popular weight-loss and diabetes medications stoked anger and pushback from users, sellers and the Alliance for Pharmacy Compounding, which represents

29.80

★★★★★4.9 (98)

🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these

24.64

★★★★★5.0 (157)

September 2, 2025: U.S. compounding restrictions have stemmed a flood of compounded semaglutide and tirzepatide – Partnership for Safe Medicines

25.11

★★★★★4.7 (84)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

23.02

★★★★★4.9 (203)

How FDA Crackdowns Are Affecting GLP-1 Use In 2025

20.15

★★★★★5.0 (176)

The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the

21.14

★★★★★4.8 (132)